Abstract 181P
Background
Intratumoral tertiary lymphoid structures (TLSs) have been associated with improved outcome in a variety of cancer patient cohorts, reflecting the key role of TLSs in the initiation of tumor-targeting immunity. Although, the clinical and biological relevance of TLSs, B cells, plasma cells and humoral adaptive immunity for patients with EOC have been previously reported, the precise immune contexture of developing TLSs, their impact the phenotypic profile of intratumoral T cells, and their influence on sensitivity to immunotherapy remain to be investigated in detail.
Methods
We harnessed spatial transcriptomics, multiplex immunofluorescence microscopy, and flow cytometry to characterize TLSs in patients with high-grade serous ovarian carcinoma (HGSOC), non-small cell lung carcinoma (NSCLC) and experimental mouse models.
Results
Here, we demonstrate that high-grade serous ovarian carcinoma (HGSOC) contains distinct immune aggregates with varying degrees of organization and maturation. Specifically, mature TLSs (mTLS) as forming only in 16% of HGSOCs with relatively elevated tumor mutational burden (TMB) were associated with an increased intratumoral density of CD8+ effector T (TEFF) cells and TIM3+PD1+, hence poorly immune checkpoint inhibitor (ICI)-sensitive, CD8+ T cells. Converesely, CD8+ T cells from immunologically hot tumors like non-small cell lung carcinoma (NSCLC) were enriched in ICI-responsive TCF1+ PD1+ T cells. Spatial B-cell profiling identified patterns of in situ maturation and differentiation that were associated with mTLSs. Moreover, B-cell depletion promoted signs of a dysfunctional CD8+ T cell compartment among tumor-infiltrating lymphocytes from freshly isolated HGSOC and NSCLC biopsies.
Conclusions
Taken together, our data demonstrate that – at odds with NSCLC – HGSOC is associated with a low density of follicular helper T cells and thus develops a limited number of mTLS that are insufficient to preserve a ICI-sensitive TCF1+PD1+ CD8+ T cell phenotype. These findings point to key quantitative and qualitative differences between mTLSs in ICI-responsive vs ICI-irresponsive neoplasms that may guide the development of alternative immunotherapies for patients with HGSOC.
Legal entity responsible for the study
The authors.
Funding
Sotio Biotech.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
90P - HAIC plus sintilimab and bevacizumab biosimilar as treatment for patients with advanced hepatocellular carcinoma (HCC): a phase II trial
Presenter: HAIBIN ZHANG
Session: Poster Display
91P - A real-world study of tislelizumab (Anti-PD-1) plus tyrosine kinase inhibitors for intermediate or advanced hepatocellular carcinoma
Presenter: Wei zhang
Session: Poster Display
92P - TAE-HAIC plus lenvatinib and PD-1 inhibitors versus TAE-HAIC plus atezolizumab and bevacizumab for unresectable hepatocellular carcinoma: A propensity score matching study
Presenter: hongjie Cai
Session: Poster Display
93P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: a real-world, retrospective, multicentric study.
Presenter: Margherita Rimini
Session: Poster Display
94P - First-line chemotherapy plus immunotherapy versus chemotherapy alone for advanced gallbladder carcinoma
Presenter: Qin-qin Liu
Session: Poster Display
95P - A single-arm, multicenter phase ? trial evaluating TQB2450 plus anlotinib combined with paclitaxel and cisplatin in first-line treatment of advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Junsheng Wang
Session: Poster Display
97P - ICI for patients with MSS metastatic colorectal cancer
Presenter: Zayana Sangadzhieva
Session: Poster Display
Resources:
Abstract
99P - Efficacy and safety of toripalimab plus metronomic chemotherapy in HER2 negative metastatic breast cancer
Presenter: Hongnan Mo
Session: Poster Display